Breaking News, Collaborations & Alliances

Chime Biologics Receives Commercial Manufacturing License

GMP commercial manufacturing license authorized by the China's NMPA demonstrates capabilities in large scale commercial production.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Chime Biologics, a contract development and manufacturing organization (CDMO), recently received its commercial manufacturing license from China’s National Medical Products Administration (NMPA). After 18 months of an intensive product development and manufacturing collaboration with LEPU Biopharma, Chime Biologics passed pre-approval inspection (PAI) including on-site inspection and GMP compliance inspection. The company was recognized for its technical expertise for late stage biologics dev...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters